Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enbridge Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while Enbridge Inc trades at $51.56 (market cap $112.62B). The key difference: Enbridge Inc is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Enbridge Inc pays a 5.34% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ENB | |
|---|---|---|
Market Cap | $29.60B | $112.62B |
Sector | Health | Energy |
52-Week High | $491.22 | $58.04 |
52-Week Low | $205.48 | $45.23 |
Enterprise Value | $27.56B | $196.53B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
ENB trades at $51.51, up 0.23% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend history with 31 consecutive years of increases. Revenue grew to $65.19B in 2025, though net income margin is expected to dip to 7.33% in 2026. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is mixed: robust infrastructure demand and a $41B project backlog support growth, but legal challenges and volatile energy markets pose risks. The stock offers a solid yield and consistent dividend growth, appealing for income investors, yet faces headwinds from regulatory scrutiny and debt levels nearing 49% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
